Xcout Intel
IKAIKA THERAPEUTICS, INC. competitors & alternatives
The 12 closest competitors and alternatives to IKAIKA THERAPEUTICS, INC. among biotechnology companies — ranked by similarity to what IKAIKA THERAPEUTICS, INC. actually does, not by market-cap band.
Subscribe to see IKAIKA THERAPEUTICS, INC.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About IKAIKA THERAPEUTICS, INC.
Ikaika Therapeutics is a biotechnology company developing first-in-class anti-fibrotic biologic therapies for patients with fibrotic diseases, including muscular dystrophy. The company's lead technology utilizes antibodies, such as IKN-001, to inhibit the activation of transforming growth factor-beta (TGF-beta) by protecting latent TGF-beta binding protein 4 (LTBP4) from protease cleavage.
IKAIKA THERAPEUTICS, INC. at a glance
IKAIKA THERAPEUTICS, INC. is a biotechnology company headquartered in United States. It has raised at least $2M across the 2 funding rounds on record. Its most recent funding round, Seed, raised $1M in October 2021. Xcout tracks 4 named people at IKAIKA THERAPEUTICS, INC., including Alexis Demonbreun (CSO).
IKAIKA THERAPEUTICS, INC. leadership
- Alexis DemonbreunCSO
- Dimitra GeorganopoulouCBO
- Elizabeth McNallyCEO & Board Member
- CHIH-KAO HUDirector
IKAIKA THERAPEUTICS, INC. funding rounds
At least $2M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | $1M | — | |
| VC Round | $1M | 1 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 IKAIKA THERAPEUTICS, INC. competitors
Ranked by semantic similarity — how close each company is to IKAIKA THERAPEUTICS, INC. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotech
Keros Therapeutics is a clinical-stage biopharmaceutical company that develops novel therapeutics targeting the transforming growth factor-beta (TGF-ß) superfamily of proteins. The company focuses on creating treatments for patients with hematological and neuromuscular disorders linked to dysfunctional protein signaling.
Similar biotechnology company
Mediar Therapeutics is a clinical-stage biotechnology company that develops novel antibody therapies to halt and reverse fibrotic diseases. The company focuses on deactivating myofibroblasts to treat conditions such as idiopathic pulmonary fibrosis (IPF), systemic sclerosis (SSc), and kidney fibrosis.
Similar biotechnology company
Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States. Its flagship investigational product, PLN-74809, is an orally administered, small-molecule, dual-selective inhibitor targeting both avß6 and avß1 integrins, which is currently progressing through three distinct Phase 2a clinical trials. The company's pipeline also includes PLN-1474, a small-molecule selective inhibitor of avß1, which has successfully completed its Phase 1 clinical assessment for treating liver fibrosis associated with nonalcoholic steatohepatitis (NASH). Furthermore, Pliant is nurturing two additional integrin-based initiatives in preclinical development: one focused on oncology, and another involving an allosteric agonistic monoclonal antibody designed to act upon an undisclosed integrin receptor for the treatment of various muscular dystrophies, including Duchenne muscular dystrophy. Founded in 2015, Pliant Therapeutics, Inc. maintains its corporate headquarters in South San Francisco, California.
Similar biotechnology company
FibroGenesis is a U.S. biotechnology company focused on developing therapies for fibrosis and related fibrotic diseases. Its work is intended to serve patients with serious disorders in which excessive scar-tissue formation damages organs or tissues.
Similar biotechnology company
4F Biotech is a biotechnology firm focused on developing innovative therapeutic approaches, screening platforms, and diagnostic tools to combat fibrosis and inflammatory processes.
Similar biotechnology company
Eleven P15 Inc. is a biotechnology company focused on developing early-detection biomarkers and genetically-targeted therapeutics for idiopathic pulmonary fibrosis (IPF). The company aims to improve diagnosis and treatment outcomes for patients suffering from this fatal lung disease.
Similar biotechnology company
FNC Biotech is a biotechnology company established in 2021 that focuses on the development of antibody therapeutics for idiopathic pulmonary fibrosis and cancer.
Similar biotechnology company
Certa Therapeutics is a private biotechnology company headquartered in Melbourne, Australia, focused on developing innovative precision therapies for the treatment of fibrotic diseases.
Similar biotechnology company
Endeavor BioMedicines, Inc. is a San Diego-based biotechnology company focused on developing novel treatments for conditions such as fibrosis.
Similar biotechnology company
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
Similar biotechnology company
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Similar biotechnology company
Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of IKAIKA THERAPEUTICS, INC. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for IKAIKA THERAPEUTICS, INC.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →